Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.

Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M.

Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):469-82. doi: 10.1586/14737167.2013.820956. Review.

PMID:
23977975
[PubMed - indexed for MEDLINE]
2.

Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.

Godman B, Wettermark B, Miranda J, Bennie M, Martin A, Malmström RE.

Int J Clin Pract. 2013 Sep;67(9):853-62. doi: 10.1111/ijcp.12130. Epub 2013 Apr 8.

PMID:
23560825
[PubMed - indexed for MEDLINE]
3.

Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.

Bennie M, Bishop I, Godman B, Barbui C, Raschi E, Campbell S, Miranda J, Gustafsson LL.

Int J Clin Pract. 2013 Feb;67(2):170-80. doi: 10.1111/ijcp.12100.

PMID:
23305478
[PubMed - indexed for MEDLINE]
4.

The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.

Fraeyman J, Van Hal G, Godman B, Beutels P.

Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):141-51. doi: 10.1586/erp.12.88.

PMID:
23402454
[PubMed - indexed for MEDLINE]
5.

Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?

Kalaba M, Godman B, Vuksanović A, Bennie M, Malmström RE.

J Comp Eff Res. 2012 Nov;1(6):539-49. doi: 10.2217/cer.12.62.

PMID:
24236473
[PubMed - indexed for MEDLINE]
6.

Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?

Bennie M, Bishop I, Godman B, Campbell S, Miranda J, Finlayson AE, Gustafsson LL.

Qual Prim Care. 2013;21(1):7-15.

PMID:
23735629
[PubMed - indexed for MEDLINE]
7.

Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries.

Godman B, Bucsics A, Burkhardt T, Schmitzer M, Wettermark B, Wieninger P.

Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):199-207. doi: 10.1586/erp.10.6.

PMID:
20384566
[PubMed - indexed for MEDLINE]
8.

Changes in the utilization of venlafaxine after the introduction of generics in Sweden.

Godman B, Persson M, Miranda J, Skiöld P, Wettermark B, Barbui C, Gustafsson LL.

Appl Health Econ Health Policy. 2013 Aug;11(4):383-93. doi: 10.1007/s40258-013-0037-x.

PMID:
23754677
[PubMed - indexed for MEDLINE]
9.

Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future.

Vončina L, Strizrep T, Godman B, Bennie M, Bishop I, Campbell S, Vlahović-Palčevski V, Gustafsson LL.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):469-79. doi: 10.1586/erp.11.42.

PMID:
21831028
[PubMed - indexed for MEDLINE]
10.

Generic atypical antipsychotic drugs in Belgium: their influence and implications.

Godman B, De Bruyn K, Miranda J, Raschi E, Bennie M, Barbui C, Simoens S.

J Comp Eff Res. 2013 Nov;2(6):551-61. doi: 10.2217/cer.13.75.

PMID:
24236794
[PubMed - indexed for MEDLINE]
11.

Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.

Godman B, Petzold M, Bennett K, Bennie M, Bucsics A, Finlayson AE, Martin A, Persson M, Piessnegger J, Raschi E, Simoens S, Zara C, Barbui C.

BMC Med. 2014 Jun 13;12:98. doi: 10.1186/1741-7015-12-98.

PMID:
24927744
[PubMed - in process]
Free PMC Article
12.

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.

Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP.

Appl Health Econ Health Policy. 2010;8(1):7-24. doi: 10.2165/11313900-000000000-00000. Review.

PMID:
20038190
[PubMed - indexed for MEDLINE]
13.

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.

Coma A, Zara C, Godman B, Agustí A, Diogène E, Wettermark B, Haycox A.

Expert Rev Pharmacoecon Outcomes Res. 2009 Dec;9(6):569-81. doi: 10.1586/erp.09.58. Review.

PMID:
19941434
[PubMed - indexed for MEDLINE]
14.

Demand-side policies to encourage the use of generic medicines: an overview.

Dylst P, Vulto A, Simoens S.

Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):59-72. doi: 10.1586/erp.12.83. Review.

PMID:
23402447
[PubMed - indexed for MEDLINE]
15.

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.

McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A.

Expert Rev Pharmacoecon Outcomes Res. 2010 Feb;10(1):73-85. doi: 10.1586/erp.09.73.

PMID:
20121565
[PubMed - indexed for MEDLINE]
16.

Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions.

Markovic-Pekovic V, Skrbić R, Godman B, Gustafsson LL.

Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):661-71. doi: 10.1586/erp.12.48.

PMID:
23186404
[PubMed - indexed for MEDLINE]
17.

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications.

Woerkom Mv, Piepenbrink H, Godman B, Metz Jd, Campbell S, Bennie M, Eimers M, Gustafsson LL.

J Comp Eff Res. 2012 Nov;1(6):527-38. doi: 10.2217/cer.12.52.

PMID:
24236472
[PubMed - indexed for MEDLINE]
18.

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.

Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, Bishop I, Bucsics A, Campbell S, Finlayson AE, Fürst J, Garuoliene K, Herholz H, Kalaba M, Laius O, Piessnegger J, Sermet C, Schwabe U, Vlahović-Palčevski VV, Markovic-Pekovic V, Vončina L, Malinowska K, Zara C, Gustafsson LL.

Front Pharmacol. 2014 Jun 17;5:106. doi: 10.3389/fphar.2014.00106. eCollection 2014. Review.

PMID:
24987370
[PubMed]
Free PMC Article
19.

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.

Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P.

Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):475-84. doi: 10.1586/erp.09.43.

PMID:
19817531
[PubMed - indexed for MEDLINE]
20.

Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.

Pichetti S, Sermet C, Godman B, Campbell SM, Gustafsson LL.

Appl Health Econ Health Policy. 2013 Jun;11(3):205-18. doi: 10.1007/s40258-013-0014-4.

PMID:
23609765
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk